IL17A and psoriasis: Much evidence suggests that the interleukin (IL)-17/IL-23 axis is a major player in the pathogenesis of psoriasis (Di Cesare et al., 2009), and several biologics targeting the IL-17/IL-23 axis were approved for the treatment of psoriatic diseases (Bai et al., 2019).